F-6 1 naba225904f6.htm FORM F-6

 

As filed with the Securities and Exchange Commission on September 4, 2015

Registration No. 333-

_____________________

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

FORM F-6

REGISTRATION STATEMENT

under

THE SECURITIES ACT OF 1933

For American Depositary Shares

of

 

NABRIVA THERAPEUTICS AG

(Exact name of issuer of deposited securities as specified in its charter)

N/A

(Translation of issuer's name into English)

 

Republic of Austria

(Jurisdiction of incorporation or organization of issuer)

 

THE BANK OF NEW YORK MELLON

(Exact name of depositary as specified in its charter)

One Wall Street, New York, New York 10286

(212) 495-1784

(Address, including zip code, and telephone number, including area code, of depositary's principal executive offices)

_______________________

The Bank of New York Mellon

ADR Division

One Wall Street, 11th Floor

New York, New York 10286

(212) 495-1784

(Address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to:

Brian D. Obergfell, Esq.

Emmet, Marvin & Martin, LLP

120 Broadway

New York, New York 10271

(212) 238-3032

It is proposed that this filing become effective under Rule 466

[ ] immediately upon filing

[ ] on (Date) at (Time).

If a separate registration statement has been filed to register the deposited shares, check the following box. [X]

CALCULATION OF REGISTRATION FEE

Title of each class
of Securities to be registered		 Amount to be registered Proposed
maximum aggregate price per unit (1)		 Proposed
maximum  aggregate offering price (1)		 Amount of registration fee
American Depositary Shares, each American Depositary Share representing Common Shares, of Nabriva Therapeutics AG. 100,000,000 American Depositary Shares $5.00 $5,000,000 $581.00
1For the purpose of this table only the term "unit" is defined as 100 American Depositary Shares.

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a) may determine.

 

 
 

The prospectus consists of the proposed Form of American Depositary Receipt included as Exhibit A to the Form of Deposit Agreement filed as Exhibit 1 to this Registration Statement, which is incorporated herein by reference.

 
 

PART I

INFORMATION REQUIRED IN PROSPECTUS

 

Item - 1. Description of Securities to be Registered

 

Cross Reference Sheet

 

 

Item Number and Caption

 

  

Location in Form of Receipt Filed Herewith as Prospectus

 

1. Name and address of depositary

 

   Introductory Article

2. Title of American Depositary Receipts and identity of deposited securities

 

   Face of Receipt, top center

Terms of Deposit:

 

    
(i)   The amount of deposited securities represented by one unit of American Depositary Receipts   Face of Receipt, upper right corner
(ii)   The procedure for voting, if any, the deposited securities   Articles number 15, 16 and 18
(iii)   The collection and distribution of dividends   Articles number 4, 12, 13, 15 and 18
(iv)  The transmission of notices, reports and proxy soliciting material   Articles number 11, 15, 16 and 18
(v)   The sale or exercise of rights   Articles number 13, 14, 15 and 18
(vi)  The deposit or sale of securities resulting from dividends, splits or plans of reorganization   Articles number 12, 13, 15, 17 and 18
(vii)  Amendment, extension or termination of the deposit agreement   Articles number 20 and 21
(viii)  Rights of holders of Receipts to inspect the transfer books of the depositary and the list of holders of Receipts   Article number 11
(ix)  Restrictions upon the right to deposit or withdraw the underlying securities   Articles number 2, 3, 4, 5, 6, 8 and 22
(x)   Limitation upon the liability of the depositary   Articles number 14, 18, 21 and 22

3. Fees and Charges

 

   Articles 7 and 8
  Item - 2. Available Information    
    Public reports furnished by issuer   Article number 11
         
 
 

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item - 3. Exhibits

a. Form of Deposit Agreement dated as of _____________, 2015, among Nabriva Therapeutics AG, The Bank of New York Mellon as Depositary, and all Owners and Holders from time to time of American Depositary Shares issued thereunder. - Filed herewith as Exhibit 1.
b. Any other agreement to which the Depositary is a party relating to the issuance of the Depositary Shares registered hereby or the custody of the deposited securities represented. - Not Applicable.  
c. Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. - See (a) above.
d. Opinion of Emmet, Marvin & Martin, LLP, counsel for the Depositary, as to legality of the securities to be registered. – Filed herewith as Exhibit 4.  
e. Certification under Rule 466. - Not Applicable.

 

Item - 4.

Undertakings

(a) The Depositary hereby undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of the ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

 

(b) If the amounts of fees charged are not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty days before any change in the fee schedule.
 
 

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on September 4, 2015.

 

Legal entity created by the agreement for the issuance of American Depositary Shares for Common Shares, of Nabriva Therapeutics AG

By: The Bank of New York Mellon,

As Depositary

 

 

By: /s/ Slawomir Soltowski

Name: Slawomir Soltowski

Title: Managing Director

 
 

Pursuant to the requirements of the Securities Act of 1933, Nabriva Therapeutics AG has caused this Registration Statement to be signed on its behalf by the undersigned thereunto duly authorized, in the City of Vienna, Austria on September 4, 2015.

NABRIVA THERAPEUTICS AG

 

By: /s/ Colin Broom

Name: Colin Broom

Title: Chief Executive Officer

 

 

Each person whose signature appears below hereby constitutes and appoints Colin Broom and Ralf Schmid, and each of them severally, his true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his name, place and stead in any and all capacities the Registration Statement and any and all amendments thereto (including post-effective amendments) and any documents in connection therewith, and to file the same with the Securities and Exchange Commission, granting unto each of said attorneys full power to act with or without the other, and full power and authority to do and perform, in his name and on his behalf, every act whatsoever which such attorneys, or any one of them, may deem necessary or desirable to be done in connection therewith as fully and to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on September 4, 2015.

 

/s/ Denise Pollard-Knight

  

/s/ Colin Broom

Denise Pollard-Knight     Colin Broom
Chairman of the Supervisory Board     Chief Executive Officer
      (Principal Executive Officer)
     
     

/s/ Axel Bolte

  

/s/ Ralf Schmid

Axel Bolte     Ralf Schmid
Deputy Chairman of the Supervisory Board     Chief Operating Officer and Chief Financial
      Officer
      (Principal Accounting Officer and Principal
      Financial Officer)
     
     
     

/s/ Chen Yu

  

/s/ Colin Broom

Chen Yu     Colin Broom
Supervisory Board Member     Authorized Representative in the United
      States
     

/s/ Chau Khuong

    
Chau Khuong    
Supervisory Board Member    
     
     
     

/s/ David Chiswell

    
David Chiswell    
Supervisory Board Member    
     
     

/s/ Charles A. Rowland, Jr.

    
Charles A. Rowland, Jr.    
Supervisory Board Member    
     
     

/s/ George H. Talbot

    
  George H. Talbot    
Supervisory Board Member    
     
 
 

 

INDEX TO EXHIBITS

Exhibit

Number Exhibit

 

1 Form of Deposit Agreement dated as of ___________, 2015, among Nabriva Therapeutics AG, The Bank of New York Mellon as Depositary, and all Owners and Holders from time to time of American Depositary Shares issued thereunder.
   
   
4 Opinion of Emmet, Marvin & Martin, LLP, counsel for the Depositary, as to legality of the securities to be registered.